We are thrilled to co-lead Alpha-9 Oncology's $175M oversubscribed Series C with Lightspeed, plus other new investors General Catalyst, RA Capital Management, Janus Henderson Investors, a16z Bio + Health, Delos Capital, Digitalis Ventures, Lumira Ventures, and abrdn. We are joining existing investors Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF PARTNERS, L.P, and Samsara BioCapital. Congrats to CEO David Hirsch and his world-class team!
About us
Ascenta Capital invests in biotechs.
- Website
-
ascentacap.com
External link for Ascenta Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Type
- Partnership
- Founded
- 2023
Employees at Ascenta Capital
Updates
-
Congratulations to Ascenta portfolio companies Cardurion Pharmaceuticals and Iambic Therapeutics for their inclusion in the 2024 Endpoints 11 List of Biotech's Most Promising Startups!
Endpoints News Announces the 2024 Winners of the Endpoints 11 Awards, Highlighting Biotech’s Most Promising Startups
businesswire.com
-
Energized to co-lead OrsoBio's oversubscribed $67M Series B round alongside Woodline Partners LP and existing investors Longitude Capital, Enavate Sciences, Samsara BioCapital, Eli Lilly and Company, and NuevaBio. Congratulations to CEO G. Mani Subramanian and his team on their impressive obesity, diabetes, and metabolic medicines. https://lnkd.in/etb3X6Ra
-
Honored to lead Cardurion Pharmaceuticals' oversubscribed $260M Series B round alongside existing investor Bain Capital Life Sciences Fund LP and new investors New Enterprise Associates (NEA), GV (Google Ventures), Fidelity Management And Research Company, Millennium, Farallon Capital Management, The Invus Group, Blue Owl Capital, Delos Capital and Digitalis Ventures. Looking forward to partnering with Peter Lawrence and his spectacular team on this next chapter!